Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Mol Genet Metab. 2021 Nov 16;134(4):330–336. doi: 10.1016/j.ymgme.2021.11.008

Figure 3.

Figure 3.

In vivo evaluation of ceftriaxone. a NPC1 disease composite score evaluation between 4 and 16 weeks for vehicle (PBS, initial n=9 and 23) and ceftriaxone (100 mg.kg−1, initial n=13 and 15) treated Npc1−/− and Npc1+/+ mice. Initial n values are for Npc1−/− and Npc1+/+ respectively). These numbers become truncated as the experiment progresses. b Kaplan-Meier survival analysis of PBS (n=15) and ceftriaxone (n=14) treated Npc1−/− mice. c Immunofluorescence quantification of CD68 in cerebellar tissue from 7-week-old PBS or ceftriaxone treated Npc1−/− mice. d Immunofluorescence quantification of GFAP in cerebellar tissue from 7-week-old PBS or ceftriaxone treated Npc1−/− mice. e Cerebellar lobule Purkinje neuron density per 100µm in 7-week-old of PBS or ceftriaxone treated Npc1−/− mice. Purkinje neurons were identified by immunostaining for calbindin. N≥6, Npc1−/− PBS (purple), Npc1−/− ceftriaxone (red), Npc1+/+ PBS (dark blue), Npc1+/+ ceftriaxone (light blue).